Bevacizumab recently received approval from the United States Food and Drug Administration for use in recurrent glioblastoma. Although, most patients tolerate bevacizumab with tolerable side effects, occasional patients sustain life-threatening complications and many others require medical management in order to continue on the drug. This chapter reviews the spectrum of bevacizumab complications in patients with malignant glioma, including mechanism when known as well as management.
About this chapter
Cite this chapter as:Dawit Aregawi, David Schiff ;
Bevacizumab Toxicity in Glioblastoma, Controversies in Neuro-Oncology Avastin and Malignant Gliomas (2010) 1: 46. https://doi.org/10.2174/978160805132811001010046
Bentham Science Publisher